Clinical impact of low-radiation computed tomography coronary angiography diagnosis for coronary artery stenosis

Study Protocol
Jian-Jun Li, MBa, Ming Zeng, MBb,*

Abstract
Background: The objective of this study aims to assess the clinic impact of low-radiation computed tomography coronary angiography (LR-CTCA) diagnosis for coronary artery stenosis (CAS).

Methods: This study will comprehensively search the following electronic databases from inception to the present: PUBMED, EMBASE, Cochrane Library, PsycINFO, Web of Science, Google, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, VIP database, WANGFANG, and China National Knowledge Infrastructure. All these electronic databases will be searched without language restrictions. All case-controlled studies on assessing the clinical impact of LR-CTCA diagnosis for patients with CAS will be included. Quality Assessment of Diagnostic Accuracy Studies tool will be utilized to evaluate the methodological quality for each qualified studies.

Results: We will assess the clinic impact of LR-CTCA diagnosis for CAS by measuring sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio.

Conclusion: The results of this study will summarize the latest evidence of LR-CTCA diagnosis for CAS.

Systematic review registration: PROSPERO CRD42019139336.

Abbreviations: CAD = coronary artery disease, CAS = coronary artery stenosis, CCSs = case-controlled studies, LR-CTCA = low-radiation computed tomography coronary angiography, PRISMA = preferred reporting items for systematic reviews and meta-analysis.

Keywords: coronary artery stenosis, low-radiation computed tomography coronary angiography, sensitivity, specificity

1. Introduction
Coronary artery disease (CAD) is often associated with poor outcome results, and also a major cause of morbidity and mortality.[1–4] It often manifests as chest pain, shortness of breath, and heart attack.[5–7] Such disorder often results from blockage or stenosis of the coronary arteries that supply the blood to the heart.[8–10] Of which, coronary artery stenosis (CAS) is the most common type, and it often occurs at the early stage of CAD.[11–12] A variety of risk factors are relevant with this condition, such as age, sex, family history, smoking, high blood pressure, high blood cholesterol levels, diabetes, overweight or obesity, physical inactivity, high stress, and unhealthy diet.[13–18] Thus, it is very important to prevent CAS with effective diagnosis tool at early stage. Low-radiation computed tomography coronary angiography (LR-CTCA) is reported to diagnose CAS at early stage accurately and effectively.[19–35] However, its results are still inconsistent. Therefore, this study will firstly assess the accurate of LR-CTCA diagnosis for patients with CAS.

2. Methods
2.1. Study registration
The protocol of this study has been registered on PROSPERO (CRD42019139336). The study will be reported in accordance to the guideline of preferred reporting items for systematic reviews and meta-analysis (PRISMA) protocol statement.[36]

2.2. Ethics and dissemination
We will not analyze individual patient data, thus, no ethic approval is required. We will plan to publish results of this study via peer-reviewed journals or conference proceedings.

2.3. Eligibility criteria
2.3.1. Types of studies. All case-controlled studies (CCSs) on assessing clinical value of LR-CTCA diagnosis for CAS will be considered for inclusion.
2.3.2. **Types of patients.** We will include patients with invasive coronary angiography diagnosis of CAS in this study regardless the gender, age, and region.

2.3.3. **Type of index test.** Index test: LR-CTCA diagnosis for CAS has been utilized in the intervention group. Reference test: invasive coronary angiography diagnosis for CAS has been used in the control group.

2.3.4. **Types of outcome measurements.** In this study, we will measure sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio.

2.4. **Search methods for identification of studies**

2.4.1. **Electronic searches.** In this study, the databases of PUBMED, EMBASE, Cochrane Library, PsycINFO, Web of Science, Google, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, VIP database, WANG-FANG, and China National Knowledge Infrastructure will be comprehensively searched from their inception to the present regardless language restrictions. We will consider all CCs of LR-CTCA diagnosis for CAS. A detailed example of search strategy for PUBMED is presented in Table 1. We will adopt similar strategies to all other electronic databases.

2.4.2. **Other resources.** Other resources, such as dissertations, conference proceedings, and reference lists of relevant reviews will be included.

2.5. **Data collection**

2.5.1. **Selection of studies.** Two independent authors will screen study eligibility according to the inclusion criteria. All divergences between 2 authors will be solved by consensus with a third author involved. The whole process consists of 2 stages. At first stage, all records will be scanned, and all duplicated and irrelevant studies will be excluded. At the second stage, full texts of the remaining studies will be read to further judge if they meet all eligibility criteria. All excluded studies will be recorded for specific reasons. The results of study selection will be shown in the PRISMA flow chart.

2.5.2. **Data collection and management.** Two independent authors will extract data from all eligible studies based on the previously developed data extraction form. A third author will help to resolve all disagreements between 2 authors via discussion. The following information will be extracted:

- (1) Study characteristics: first author, year of publication, design, study setting, sample size, and so on;
- (2) Patient characteristics: patient demographics, inclusion and exclusion criteria, and so on;
- (3) Interventional and reference tests: time, methods of samples, study period, and so on;
- (4) Outcomes: true positives, false positives, and so on.

2.5.3. **Dealing with missing data.** Whenever there is insufficient or missing data, we will directly contact primary authors of original studies to require those data. If we cannot get back those data, we will analyze the available data only.

2.6. **Methodological quality assessment**

Two independent authors will assess methodological quality for each qualified study using the Quality Assessment of Diagnostic Accuracy Studies tool. Any different opinions regarding the methodological quality assessment between 2 authors will be solved by a third experienced author through discussion.

2.7. **Statistical analysis**

RevMan V.5.3 and Stata 12.0 software will be used to carry out statistical analysis. We will calculate descriptive statistics and 95% confidence intervals. Additionally, we will also operate descriptive forest plot and a summary receiver operating characteristic plot.

2.7.1. **Assessment of heterogeneity.** We will use $I^2$ statistic to investigate heterogeneity among eligible studies. The value of $I^2 \leq 50\%$ means low heterogeneity. On the other hand, the value of $I^2 > 50\%$ means significant heterogeneity.

2.7.2. **Data synthesis.** If there is low heterogeneity ($I^2 \leq 50\%$), we will pool the data and carry out meta-analysis. If there is significant heterogeneity ($I^2 > 50\%$), we will carry out subgroup analysis. We will pool the data and perform meta-analysis if there is low heterogeneity after subgroup analysis. Otherwise, we will not carry out meta-analysis if there is significant heterogeneity after subgroup analysis. In addition, we will carry out the bivariate random-effects regression to summarize the estimates of sensitivity and specificity.

2.8. **Additional analysis**

2.8.1. **Subgroup analysis.** We will conduct subgroup analysis based on the different study characteristics, and patients.
2.8.2. Sensitivity analysis. We will carry out sensitivity analysis to explore the stability and robustness of pooled outcome results by removing the low methodological quality studies.

2.8.3. Reporting bias. We will perform funnel plots and relevant regression tests to check if there is reporting bias in this study.

3. Discussion

Although many studies utilized LR-CTCA diagnosis for CAS, there is no comprehensive systematic review comparing the diagnosis accurate of LR-CTCA with other diagnosis tools. We hope this study will provide the most current available evidence to present whether LR-CTCA diagnosis is more accurate than other diagnosis tools in the patients diagnosed as CAS. The results of this study will provide helpful evidence for the LR-CTCA diagnosis in patients with CAS. However, this study may still have several limitations. First, although this study tries to search literature records comprehensively, this study may still miss some potential studies. Second, different methodological qualities may cause high heterogeneity.

Author contributions

Conceptualization: Jian-Jun Li, Ming Zeng.
Data curation: Jian-Jun Li, Ming Zeng.
Formal analysis: Jian-Jun Li, Ming Zeng.
Investigation: Ming Zeng.
Methodology: Jian-Jun Li.
Project administration: Ming Zeng.
Resources: Jian-Jun Li.
Software: Jian-Jun Li.
Supervision: Ming Zeng.
Validation: Jian-Jun Li, Ming Zeng.
Visualization: Jian-Jun Li, Ming Zeng.
Writing – original draft: Jian-Jun Li, Ming Zeng.
Writing – review and editing: Jian-Jun Li, Ming Zeng.

References

[1] ELguindy MS, Elguindy AM. Aneurysmal coronary artery disease: an overview. Glob Cardiol Sci Pract 2017;2017:e201726.
[2] Head SJ, Milosevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 2018;391:939–48.
[3] Akładad M, Monteiro MC. Current treatment of significant left main coronary artery disease: a review. Trends Cardiovasc Med 2018;28:357–64.
[4] Mack M, Gopal A. Epidemiology, traditional and novel risk factors in coronary artery disease. Heart Fail Clin 2016;12:1–0.
[5] Das D, Asher A, Ghosh AK. Cancer and coronary artery disease: common associations, diagnosis and management challenges. Curr Treat Options Oncol 2019;20:46.
[6] Braun MM, Stevens WA, Barstow CH. Stable coronary artery disease: treatment. Am Fam Physician 2018;97:376–84.
[7] Cagle SD Jr, Cooperstein M. Coronary artery disease: diagnosis and management. Prim Care 2018;45:45–61.
[8] Kobayashi J. Changing strategy for aortic stenosis with coronary artery disease by transcatheter aortic valve implantation. Gen Thorac Cardiovasc Surg 2013;61:663–8.
[9] Stefani G, Stortscky S, Meier B, et al. Severe aortic stenosis and coronary artery disease. EuroIntervention 2013;9:563–8.
[10] Visk SA, Tian DH, Liou K, et al. Systematic review of percutaneous coronary intervention and transcatheter aortic valve implantation for concomitant aortic stenosis and coronary artery disease. Int J Cardiol 2015;187:453–5.
[11] Mazzone A, Vennari L, Berti S. Aortic valve stenosis and coronary artery disease: pathophysiological and clinical links. J Cardiovasc Med (Hagerstown) 2007;8:983–9.
[12] Moreira DM, da Silva RL, Vieira JL, et al. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Am J Cardiovasc Drugs 2015;15:1–1.
[13] Parvand M, Rayner-Harley E, Sledaj T. Recent developments in sex-related differences in presentation, prognosis, and management of coronary artery disease. Can J Cardiol 2018;34:390–9.
[14] Collet C, Capodanno D, Oumma Y, et al. Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nat Rev Cardiol 2018;15:321–31.
[15] Malahijl M, Mahanraj JJ. Imaging to stratify coronary artery disease risk in asymptomatic patients with diabetes. Methodist DeBakey Cardiovasc J 2018;14:266–72.
[16] Wada H, Miyachi K, Daida H. Gender differences in the clinical features and outcomes of patients with coronary artery disease. Expert Rev Cardiac Ther 2019;17:127–33.
[17] Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 2019;234:16812–23.
[18] Naito R, Miyachi K. Coronary artery disease and type 2 diabetes mellitus. Int Heart J 2017;58:475–80.
[19] Kajander S, Joustra Lab, Saraste M, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. Circulation 2010;122:603–13.
[20] Maffei E, Seitun S, Martini C, et al. CT coronary angiography and exercise ECG in a population with chest pain and low-to-intermediate pre-test likelihood of coronary artery disease. Heart 2010;96:1971–9.
[21] Øvrehus KA, Marwan M, Bjerke HE, et al. Reproducibility of coronary plaque detection and characterization using low radiation dose coronary computed tomographic angiography in patients with intermediate likelihood of coronary artery disease (ResCAN study). Int J Cardiovasc Imaging 2012;28:889–99.
[22] Dharampal AS, Rossi A, de Feyter PJ. Computed tomography-coronary angiography in the detection of coronary artery disease. J Cardiovasc Med (Hagerstown) 2011;12:534–61.
[23] Bhutani S, Tobis J, Gevorgyan K, et al. Accuracy of stress myocardial perfusion imaging to diagnose coronary artery disease in end stage liver disease patients. Am J Cardiol 2013;111:1057–61.
[24] Gosling O, Morgan-Hughes G, Iyengar S, et al. Computed tomography to diagnose coronary artery disease: a reduction in radiation dose increases applicability. Clin Radiol 2013;68:340–5.
[25] Groothuis JG, Beek AM, Brinkman SL, et al. Combined non-invasive functional and anatomical diagnostic work-up in clinical practice: the magnetic resonance and computed tomography in suspected coronary artery disease (MARCC) study. Eur Heart J 2013;34:1990–8.
[26] Hou Y, Ma Y, Fan W, et al. Diagnostic accuracy of low-dose 256-slice multi-detector coronary CT angiography using iterative reconstruction in patients with suspected coronary artery disease. Eur Radiol 2014;24:3–11.
[27] Farzaneh-Far A, Steigner M, Kwong RY. Applications and limitations of cardiac computed tomography in the evaluation of coronary artery disease. Coron Artery Dis 2013;24:606–12.
[28] Fontone G, Andretti D, Baggiaro A, et al. Functional relevance of coronary artery disease by cardiac magnetic resonance and cardiac computed tomography: myocardial perfusion and fractional flow reserve. Biomed Res Int 2015;2015:297696.
[29] Engbers EM, Timmer JR, Ottervanger JP, et al. Sequential SPECT/CT imaging for detection of coronary artery disease in a large cohort: evaluation of the need for additional imaging and radiation exposure. J Nucl Cardiol 2017;24:212–23.
[30] Ulimoen GR, Ofstad AP, Endresen K, et al. Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes—a cross-sectional study. BMC Cardiovasc Disord 2015;15:147.
[31] Treibel TA, Rossi A, Pugliese F, et al. Functional assessment of coronary artery disease by cardiac computed tomography. Expert Rev Cardiovasc Ther 2017;15:657–63.
[32] Dantas RN Jr, Assunção AN Jr, Marques IA, et al. Myocardial perfusion in patients with suspected coronary artery disease: comparison between 320-MDCT and rubidium-82 PET. Eur Radiol 2018;28:2665-74.

[33] Richards CE, Obaid DR. Low-dose radiation advances in coronary computed tomography angiography in the diagnosis of coronary artery disease. Curr Cardiol Rev 2019;15:304-15.

[34] Lipton MJ, Holt WW. Computed tomography for patient management in coronary artery disease. Circulation 1991;84(3 Suppl):I72–80.

[35] Pazhenkottil AP, Herzog BA, Husmann L, et al. Non-invasive assessment of coronary artery disease with CT coronary angiography and SPECT: a novel dose-saving fast-track algorithm. Eur J Nucl Med Mol Imaging 2010;37:522–7.

[36] Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.

[37] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.

[38] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.